Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers

Khurram, Syed Ali; Speight, Paul M.

doi:10.1007/s12105-018-0917-3

Cited by 38 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SC is typically negative for DOG1 membranous expression on immunohistochemistry. When present, DOG1 membranous expression is usually weak and limited to the periphery of tumour nests, or decorates the glandular lumina [2,13]. This is in contrast to acinic cell carcinoma (AcCC), which typically demonstrates diffuse canicular DOG1 expression [13].…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemically, SC typically shows strong diffuse expression for S100 protein, GATA3 and mammoglobin, but is negative for DOG1 [2,13,28]. In contrast, ETV6 rearranged low-grade SNAC typically shows strong apical membranous staining with DOG1, with only scattered single cells and tumor clusters expressing S100 protein.…”

Section: Discussionmentioning

confidence: 99%

“…(Mammary analogue) Secretory carcinoma (SC) was first described in 2010 by Skalova et al in a series of 16 tumors from the parotid gland and minor salivary glands of the oral cavity, with histomorphologic and immunohistochemical features strongly reminiscent of secretory carcinoma of the breast [1]. On immunohistochemistry, SC is typically positive for S100 protein, mammoglobin, GATA3, STAT5 and MUC4, but negative for p63 and DOG1 [2][3][4]. Like secretory carcinoma of the breast, salivary gland SC typically demonstrates a t(12;15) (p13; q25) ETV6-NTRK3 translocation.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

(Mammary Analogue) Secretory Carcinoma of the Nasal Cavity: Report of a Rare Case with p63 and DOG1 Expression and Uncommon Exon 4–Exon 14 ETV6-NTRK3 Fusion Diagnosed with Next Generation Sequencing

Loh

Vaněček

et al. 2019

Head and Neck Pathol

View full text Add to dashboard Cite

We present a 72 years old male with a left nasal cavity (mammary analogue) secretory carcinoma (SC) which exhibited classical morphological features on light microscopical examination, diffuse strong S100 and mammoglobin positivity on immunohistochemistry, and ETV6-NTRK3 gene fusion on next generation sequencing (NGS) analysis. Unusual features of this tumor are expression of p63 and DOG1 on immunohistochemistry and the atypical junction between Exon 4 of the ETV6 gene and Exon 14 of the NTRK3 gene.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

(Mammary Analogue) Secretory Carcinoma of the Nasal Cavity: Report of a Rare Case with p63 and DOG1 Expression and Uncommon Exon 4–Exon 14 ETV6-NTRK3 Fusion Diagnosed with Next Generation Sequencing

Loh

Vaněček

et al. 2019

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…In salivary gland cytology, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are often used to aid diagnosis 3,5,6 . DOG1 and, to a lesser extent, SOX‐10 have been the primary markers of AcCC, although neither is entirely sensitive or specific 7‐14 . Also, AcCC is typically negative for p40 and p63 by IHC 12,14 .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma

Skaugen

Seethala

Chiosea

et al. 2020

Cancer Cytopathology

View full text Add to dashboard Cite

Background Acinic cell carcinoma (AcCC) is diagnostically challenging on fine‐needle aspiration because it can mimic several other neoplasms or even normal acinar tissue. Immunopositivity for DOG1, especially circumferential membranous staining, can support the diagnosis of AcCC but is not entirely specific, and it is prone to technical and interpretive challenges on small specimens. NR4A3 (nuclear receptor subfamily 4 group A member 3) translocation and nuclear NR4A3 overexpression were recently described in the majority of AcCCs. Here, the authors evaluate the performance of NR4A3 immunohistochemistry (IHC) and NR4A3 break‐apart fluorescence in situ hybridization (FISH) on cell block preparations and compare them with DOG1 IHC in distinguishing AcCC from other entities in the differential diagnosis. Methods The authors identified 34 cytology cell blocks with lesional cells, including 11 specimens of AcCC (2 of which derived from 1 patient and showed high‐grade transformation) as well as 2 secretory carcinomas, 7 salivary duct carcinomas, 4 mucoepidermoid carcinomas, 3 oncocytomas, 3 renal cell carcinomas, and 6 specimens containing nonneoplastic salivary gland tissue. NR4A3 IHC, DOG1 IHC, and NR4A3 FISH were attempted for all cases. Results NR4A3 IHC had 81.8% sensitivity and 100% specificity for AcCC, whereas NR4A3 FISH had 36.4% sensitivity and 100% specificity, although 4 cases (3 mucoepidermoid carcinomas and 1 salivary gland tissue sample) could not be analyzed because of low cellularity. Notably, no normal acinar tissue specimens showed NR4A3 positivity by IHC or FISH. In addition, DOG1 IHC had 72.7% sensitivity and 92% specificity. Conclusions NR4A3 IHC is highly specific for the diagnosis of AcCC and is more sensitive than DOG1 IHC and NR4A3 FISH. In addition, NR4A3 IHC performance is not improved by the inclusion of DOG1 IHC. Finally, NR4A3 positivity resolves the perennial problem of distinguishing AcCC from normal acinar tissue.

show abstract

“…Further, in contrast to acinic cell carcinoma with oncocytic cells, OC is negative for SOX10 and DOG1 [34]. DOG1 is an acinar and intercalated duct marker in salivary gland tissue and therefore not surprisingly negative in OCs [35]. A novel possibly promising immunohistochemical marker for oncocytic cells is the socalled BSND marker.…”

Section: Oncocytomamentioning

confidence: 99%

Analysis of the Clinical Relevance of Histological Classification of Benign Epithelial Salivary Gland Tumours

et al. 2019

View full text Add to dashboard Cite

Introduction: A vast increase in knowledge of numerous aspects of malignant salivary gland tumours has emerged during the last decade and, for several reasons, this has not been the case in benign epithelial salivary gland tumours. We have performed a literature review to investigate whether an accurate histological diagnosis of the 11 different types of benign epithelial salivary gland tumours is correlated to any differences in their clinical behaviour. Methods: A search was performed for histological classifications, recurrence rates and risks for malignant transformation, treatment modalities, and prognosis of these tumours. The search was performed primarily through PubMed, Google Scholar, and all versions of WHO classifications since 1972, as well as numerous textbooks on salivary gland tumours/head and neck/pathology/oncology. A large number of archival salivary tumours were also reviewed histologically. Results: Pleomorphic adenomas carry a considerable risk (5-15%) for malignant Henrik Hellquist and Antó nio Paiva-Correia contributed to the manuscript equally and are co-first authors.

show abstract

Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers

Cited by 38 publications

References 35 publications

(Mammary Analogue) Secretory Carcinoma of the Nasal Cavity: Report of a Rare Case with p63 and DOG1 Expression and Uncommon Exon 4–Exon 14 ETV6-NTRK3 Fusion Diagnosed with Next Generation Sequencing

(Mammary Analogue) Secretory Carcinoma of the Nasal Cavity: Report of a Rare Case with p63 and DOG1 Expression and Uncommon Exon 4–Exon 14 ETV6-NTRK3 Fusion Diagnosed with Next Generation Sequencing

Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma

Analysis of the Clinical Relevance of Histological Classification of Benign Epithelial Salivary Gland Tumours

Contact Info

Product

Resources

About